DekaBank Deutsche Girozentrale Has $675.06 Million Stake in Johnson & Johnson $JNJ

DekaBank Deutsche Girozentrale trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,411,321 shares of the company’s stock after selling 71,750 shares during the quarter. Johnson & Johnson accounts for about 1.2% of DekaBank Deutsche Girozentrale’s holdings, making the stock its 10th largest position. DekaBank Deutsche Girozentrale owned about 0.18% of Johnson & Johnson worth $675,062,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Apexium Financial LP grew its stake in shares of Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock valued at $3,978,000 after buying an additional 2,310 shares during the last quarter. Avanza Fonder AB boosted its stake in Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after acquiring an additional 6,566 shares in the last quarter. Joel Isaacson & Co. LLC grew its stake in shares of Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after buying an additional 2,526 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after purchasing an additional 4,816 shares during the last quarter. Finally, Klingman & Associates LLC lifted its stake in shares of Johnson & Johnson by 13.4% in the first quarter. Klingman & Associates LLC now owns 16,984 shares of the company’s stock worth $2,817,000 after buying an additional 2,005 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.9%

NYSE:JNJ opened at $191.93 on Wednesday. The stock has a fifty day simple moving average of $181.27 and a 200-day simple moving average of $165.37. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market cap of $462.23 billion, a price-to-earnings ratio of 18.53, a price-to-earnings-growth ratio of 2.28 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The company had revenue of $24.02 billion for the quarter. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Barclays upped their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Stifel Nicolaus lifted their target price on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. HSBC upped their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Morgan Stanley set a $190.00 price target on Johnson & Johnson in a report on Wednesday, October 15th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $200.06.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.